Switch theme
Sign up to access all valuation multiples
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its product pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
2015
23
LTM Revenue $0.6M
Last FY EBITDA -$22.5M
$10.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
vTv Therapeutics has a last 12-month revenue (LTM) of $0.6M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, vTv Therapeutics achieved revenue of $1.0M and an EBITDA of -$22.5M.
vTv Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See vTv Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.6M | XXX | $1.0M | XXX | XXX | XXX |
| Gross Profit | $0.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$22.5M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -2214% | XXX | XXX | XXX |
| EBIT | -$26.6M | XXX | -$24.2M | XXX | XXX | XXX |
| EBIT Margin | -4454% | XXX | -2378% | XXX | XXX | XXX |
| Net Profit | -$20.9M | XXX | -$18.5M | XXX | XXX | XXX |
| Net Margin | -3504% | XXX | -1815% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, vTv Therapeutics's stock price is $16.
vTv Therapeutics has current market cap of $41.6M, and EV of $10.7M.
See vTv Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10.7M | $41.6M | XXX | XXX | XXX | XXX | $-3.32 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, vTv Therapeutics has market cap of $41.6M and EV of $10.7M.
vTv Therapeutics's trades at 10.5x EV/Revenue multiple, and -0.5x EV/EBITDA.
Equity research analysts estimate vTv Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
vTv Therapeutics has a P/E ratio of -2.0x.
See valuation multiples for vTv Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $41.6M | XXX | $41.6M | XXX | XXX | XXX |
| EV (current) | $10.7M | XXX | $10.7M | XXX | XXX | XXX |
| EV/Revenue | 17.9x | XXX | 10.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.5x | XXX | XXX | XXX |
| EV/EBIT | -0.4x | XXX | -0.4x | XXX | XXX | XXX |
| EV/Gross Profit | 17.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.0x | XXX | -2.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialvTv Therapeutics's revenue per employee in the last FY averaged $44K, while opex per employee averaged $1.1M for the same period.
vTv Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
vTv Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for vTv Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -2214% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $44K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1135% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 2478% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
vTv Therapeutics acquired XXX companies to date.
Last acquisition by vTv Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . vTv Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was vTv Therapeutics founded? | vTv Therapeutics was founded in 2015. |
| Where is vTv Therapeutics headquartered? | vTv Therapeutics is headquartered in United States of America. |
| How many employees does vTv Therapeutics have? | As of today, vTv Therapeutics has 23 employees. |
| Who is the CEO of vTv Therapeutics? | vTv Therapeutics's CEO is Mr. Paul J. Sekhri. |
| Is vTv Therapeutics publicy listed? | Yes, vTv Therapeutics is a public company listed on NAS. |
| What is the stock symbol of vTv Therapeutics? | vTv Therapeutics trades under VTVT ticker. |
| When did vTv Therapeutics go public? | vTv Therapeutics went public in 2015. |
| Who are competitors of vTv Therapeutics? | Similar companies to vTv Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of vTv Therapeutics? | vTv Therapeutics's current market cap is $41.6M |
| What is the current revenue of vTv Therapeutics? | vTv Therapeutics's last 12 months revenue is $0.6M. |
| What is the current EV/Revenue multiple of vTv Therapeutics? | Current revenue multiple of vTv Therapeutics is 17.9x. |
| Is vTv Therapeutics profitable? | Yes, vTv Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
